Wedbush Initiates Coverage On Keros Therapeutics with Outperform Rating, Announces Price Target of $86
Portfolio Pulse from richadhand@benzinga.com
Wedbush analyst Andreas Argyrides has initiated coverage on Keros Therapeutics (NASDAQ:KROS) with an Outperform rating and a price target of $86.
July 31, 2023 | 1:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush has initiated coverage on Keros Therapeutics with an Outperform rating and a price target of $86, which could positively impact the company's stock.
Analyst ratings and price targets can significantly influence a company's stock price. In this case, Wedbush's Outperform rating and high price target for Keros Therapeutics suggest a positive outlook for the company, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100